Daito PharmaceuticalDaito Pharmaceutical Co., Ltd.4577東証プライム医薬品FY ending May 2026, consolidated, J-GAAP

Daito Pharmaceutical FY ending May 2020 results

Daito Pharmaceutical brought in ¥45B in revenue.

Out of every ¥100 of sales, about ¥12 is left as operating profit.

Where the money goes

For every ¥100 Daito Pharmaceutical sells, how much goes where, and how much is kept.

FY ending May 2020

Margin funnel (derived from reported values)Gross margin 21.1% → Operating margin 11.9% → Net margin 8.8%

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第82期(2023/06/01－2024/05/31)
ID S100UAWW2024-08-30Open
EDINET (FSA Japan)
有価証券報告書－第80期(令和3年6月1日－令和4年5月31日)
ID S100P2X32022-08-25Open
EDINET (FSA Japan)
有価証券報告書－第79期(令和2年6月1日－令和3年5月31日)
ID S100MCBH2021-08-26Open

Extracted from XBRL: 49 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.